An observational study in Psoriasis, sponsored by Mindera Health. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-27.
Sponsored by Mindera Health · Observational
A 16 week study to examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 396 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Mindera Health is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male and female subjects who are 18 years of age or older with a diagnosis of psoriasis.
Exclusion Criteria
The entire duration of the study, including the screening period, will be approximately 16 weeks. Mindera Kit will be applied with applicator and left on the skin for 5 minutes, and once removed, the investigational product (IP) will be placed in a buffer solution, sealed, labeled and sent to Mindera for processing.
Also known as: MK Patch, Microdermal Patch
Observation of on therapy transcriptomics to potentially aid in new therapeutic targets
To examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects by collecting RNA and examining changes in PASI scores at the Week 4, 12, and 16 timepoints.
Time frame: 16 weeks
No study locations are listed for this record.
Plan to share: No — In order to protect patient privacy genetic data will not be shared outside of the study without further patient consent to do so. If other researchers would like access to the data they must reach out to the patients themselves.
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.